Koortslipcrème (Aciclovir)

Aciclovir penetrates virus‑infected skin cells and is converted by viral enzymes into a triphosphate form that blocks viral DNA polymerase. This stops viral DNA synthesis, limiting replication of herpes viruses and allowing the immune system to clear the infection more effectively.

The specific amount and frequency of Koortslipcrème application are determined by the prescribing healthcare professional based on the type and severity of the lesion, patient age, and clinical guidelines. Patients should follow the prescriber’s instructions precisely.

Safety data for topical aciclovir during pregnancy and lactation are limited. Healthcare providers usually weigh the potential benefits against any unknown risks before prescribing. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their doctor.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with oral antivirals such as aciclovir tablets, Koortslipcrème delivers the drug directly to the lesion, providing high local concentrations with minimal systemic exposure. It is often preferred for mild to moderate outbreaks where systemic therapy is not required.

Koortslipcrème should be stored below 25 °C in its original packaging, protected from moisture and direct sunlight. Keeping the cream at a stable, room‑temperature environment helps maintain its potency and prevents degradation.

The cream is applied thinly to clean, dry skin over the affected area, typically five times daily or as directed by a healthcare professional. Hands should be washed before and after application, and the product should not be used on open wounds or mucous membranes.

Serious risks, though rare, include severe allergic reactions such as contact dermatitis, urticaria, or anaphylaxis. If any signs of a systemic allergic response appear—such as swelling of the face, difficulty breathing, or widespread rash—medical attention should be sought immediately.

Individuals with a known hypersensitivity to aciclovir, other nucleoside analogues, or any component of the cream formulation should avoid its use. It is also contraindicated on extensively damaged or infected skin where the product cannot be applied safely.